Abstract
Nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) expression is upregulated not only by NSAIDs such as sulindac sulfide, but also by several antitumorigenic dietary compounds, suggesting that NAG-1 is a specific target for the development of effective anticancer agents. Despite being a downstream target of p53, NAG-1 induction is both p53-dependent and p53-independent. It is not clear whether NAG-1 induction is the responsible factor in cancer cell apoptosis with mutated p53. In this study, we report that NAG-1 induction alone cannot determine apoptotic cell fate in colon cancer cells. Although docetaxel induced an increase in NAG-1 and apoptosis in both HCT-116 (wild-type p53) and HT-29 (mutant p53) colon cancer cells, NAG-1 knockdown with siRNA prevented docetaxel-induced cell death in only HCT-116 cells. Docetaxel decreased Bcl-2 in HCT-116 cells, which have functionally active p53, according to luciferase reporter gene analyses, and docetaxel-induced cell death and changes in Bcl-2 and NAG-1 expression were blocked by PFT-α, a p53 inhibitor. In HT-29 cells with functionally inactive p53, the docetaxel-induced Bcl-xL decrease, NAG-1 increase, and cell death were not blocked by PFT-α. On the other hand, sulindac sulfide at concentrations that significantly induced NAG-1 did not decrease cell viability comparable to docetaxel, and it did not affect the level of p53, Bax, Bcl-2, and Bcl-xL in either cell line. The present study demonstrates that p53-dependent NAG-1 induction is linked to cell death and that NAG-1 induction without accompanying alteration of antiapoptosis protein Bcl-2 family members may not lead to cancer cell death.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baek, S. J., Kim, K. S., Nixon, J. B., Wilson, L. C., and Eling, T. E., Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol., 59, 901–908 (2001).
Baek, S. J., Wilson, L. C., and Eling, T. E., Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis, 23, 425–434 (2002).
Baek, S. J., Kim, J., Nixon, J. B., DiAugustine, R. P., and Eling, T. E., Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J. Biol. Chem., 279, 6883–6892 (2004).
Baek, S. J., Okazaki, R., Lee, S. H., Martinez, J., Kim, J. S., Yamaguchi, K., Mishina, Y., Martin, D. W., Shoieb, A., McEntee, M. F., and Eling, T. E., Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology, 131, 1553–1560 (2006).
Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X. J., Ramonetti, J. T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., and Bertagnolli, M. M., Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56, 2556–2560 (1996).
Botton, F. G. Jr., Baek, S. J., Jennifer, B. N., and Thomas, E. E., Diallyl Disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J. Nutr., 132, 773–778 (2002).
Boyle, J. O., Hakim, J., Koch, W., van der Riet, P., Hruban, R. H., Roa, R. A., Correo, R., Eby, Y. J., Ruppert, J. M., and Sidransky, D., The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res., 53, 4477–4480 (1993).
Colevas, A. D., Norris, C. M., Tishler, R. B., Fried, M. P., Gomolin, H. I., Amrein, P., Nixon, A., Lamb, C., Costello, R., Barton, J., Read, R., Adak, S., and Posner, M. R., Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J. Clin. Oncol., 17, 3503–3511 (1999).
Eisenhauer, E. A. and Vermorken, J. B., The taxoids: Comparative clinical pharmacology and therapeutic potential. Drugs, 55, 5–30 (1998).
Eling, T. E., Baek, S. J., Shim, M. S., and Lee, C. H., NSAID activated gene (NAG-1), a modulator of tumorigenesis. J. Biochem. Mol. Biol., 39, 649–655 (2006).
Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., Staiano-Coico, L., Shiff, S. I., and Rigas, B., Effects of nonsteroidal anti-inflam matory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol., 52, 237–245 (1996).
Herschman, H. R., Prostaglandin synthase 2. Biochim. Biophys. Acta, 1299, 125–140 (1996).
Huang, Y., He, Q., Hillman, M. J., Rong, R., and Sheikh, M. S., Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res., 61, 6918–6924 (2001).
Iguchi, G., Chrysovergis, K., Lee, S. H., Baek, S. J., Langenbach, R., and Eling, T. E., A reciprocal relationship exists between non-steroidal anti-inflammatory drugactivated gene-1 (NAG-1) and cyclooxygenase-2. Cancer Lett., 282, 152–158 (2009).
Kelly, J. A., Lucia, M. S., and Lambert, J. R., p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Cancer Lett., 277, 38–47 (2009).
Köhne, C. H., Schöffski, P., Wilke, H., Käufer, C., Andreesen, R., Ohl, U., Klaasen, U., Westerhausen, M., Hiddemann, W., Schott, G., Harstick, A., Bade, J., Horster, A., Schubert, U., Hecker, H., Dörken, B., and Schmoll, H. J., Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J. Clin. Oncol., 16, 418–426 (1998).
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., and Gudkov, A. V., A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 285, 1733–1737 (1999).
Lee, S. H., Kim, J. S., Yamaguchi, K., Eling, T. E., and Baek, S. J., Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem. Biophys. Res. Commun., 328, 63–69 (2005).
Lee, S. H., Yamaguchi, K., Kim, J. S., Eling, T. E., Safe, S., Park, Y., and Baek, S. J., Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis, 27, 972–981 (2006).
Leigh, C. W., Baek, S. J., Allison, C., and Thomas, E. E., Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int. J. Cancer, 105, 747–753 (2003).
Lyseng-Williamson, K. A. and Fenton, C., Docetaxel: a review of its use in metastatic breast cancer. Drugs, 65, 2513–2531 (2005).
Murphy, V. J., Yang, Z., Rorison, K. A., and Baldwin, G. S., Cyclooxygenase-2-selective antagonists do not inhibit growth of colorectal carcinoma cell lines. Cancer Lett., 122, 25–30 (1998).
Patsos, H. A., Hicks, D. J., Greenhough, A., Williams, A. C., and Paraskeva, C., Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem. Soc. Trans., 33, 712–714 (2005).
Shiff, S. J., Qiao, L., Tsai, L. L., and Rigas, B., Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest., 96, 491–503 (1995).
Schiff, S. J., Koutsos, M. I., Qiao, L., and Rigas, B., Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects in cell cycle and apoptosis. Exp. Cell Res., 222, 179–188 (1996).
Taketo, M. M., Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst., 90, 1529–1536 (1998a).
Taketo, M. M., Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl. Cancer Inst., 90, 1609–1620 (1998b).
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Kim, N. C., Oudard, S., Theodore, C., James, N. D., Turesson, I., Rosenthal, M. A., and Eisenberger, M. A., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 351, 1502–1512 (2004).
Wang, D. and Dubois, R. N., The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene, 29, 781–788 (2010).
Wang, L. G., Liu, X. M., Kreis, W., and Budman, D. R., The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol., 44, 355–361 (1999).
Watson, A. J., Chemopreventive effects of NSAIDs against colorectal cancer: Regulation of apoptosis and mitosis by COX-1 and COX-2. Histol. Histopathol., 13, 591–597 (1998).
Wilson, L. C., Baek, S. J., Call, A., and Eling, T. E., Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int. J. Cancer, 105, 747–753 (2003).
Yvon, A. M., Wadsworth, P., and Jordan, M. A., Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell, 10, 947–959 (1999).
Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., and Vogelstein, B., Role of BAX in the apoptotic response to anticancer agents. Science, 290, 989–992 (2000).
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Kim, IY., Park, SY., Kang, Y. et al. Role of nonsteroidal anti-inflammatory drug-activated gene-1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 status. Arch. Pharm. Res. 34, 323–330 (2011). https://doi.org/10.1007/s12272-011-0219-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-0219-8